Diagnosis of cutaneous T-cell lymphoma following exposure to biologic agents for atopic dermatitis: A retrospective cohort study from a single tertiary cancer center

Affiliations

¹ Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
² Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.
³ Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
⁴ Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
⁵ Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: gellers@mskcc.org.

Viviane Liao et al. J Am Acad Dermatol. 2025 Jun.

. 2025 Jun;92(6):1394-1395.

doi: 10.1016/j.jaad.2025.01.088. Epub 2025 Feb 1.

¹ Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
² Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.
³ Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
⁴ Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
⁵ Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: gellers@mskcc.org.

No abstract available

Keywords: JAKi; Sezary; atopic dermatitis; cutaneous t-cell lymphoma; dupilumab; mycosis fungoides; tralokinumab; upadacitinib.

Conflict of interest statement

Conflicts of interest None disclosed.

1. Park A, Wong L, Lang A, et al. Cutaneous T-cell lymphoma following dupilumab use: a systematic review. Int J Dermatol. 2023;62(7):862–876. - PubMed
1. Vahabi SM, Bahramian S, Esmaeili F, et al. JAK inhibitors in cutaneous T-cell lymphoma: friend or Foe? a systematic review of the published literature. Cancers (Basel). 2024;16(5):861. - PMC - PubMed
1. Hasan I, Parsons L, Duran S, et al. Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study. J Am Acad Dermatol. 2024;91(2):255–258. - PubMed
1. Lavin L, Dusza S, Geller S. Cutaneous T-cell lymphoma after dupilumab use: a real-world pharmacovigilance study of the FDA adverse event reporting system. J Invest Dermatol. 2025; 145:211–214.e1. - PMC - PubMed
1. Moskowitz AJ, Ghione P, Jacobsen E, et al. A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas. Blood. 2021; 138(26):2828–2837. - PMC - PubMed